Hidroferol (Calcifediol)

Hidroferol (calcifediol) is employed in clinical practice to correct low vitamin D status and to support calcium metabolism in several settings.

• Treatment of documented vitamin D deficiency in adults and children.
• Management of secondary hyperparathyroidism associated with chronic kidney disease.
• Adjunct therapy for osteoporosis or osteomalacia when rapid correction of vitamin D is desired.
• Support for patients with malabsorption syndromes that limit conversion of vitamin D3 to its active forms.
• Use in individuals on long‑term glucocorticoid therapy to mitigate bone loss.

• Calcifediol (25‑hydroxyvitamin D3) is the primary circulating form of vitamin D and is converted in the kidneys to calcitriol, the hormonally active form. Calcitriol binds to the vitamin D receptor (VDR) in target cells, regulating gene transcription that enhances intestinal calcium and phosphate absorption, modulates bone remodeling, and influences parathyroid hormone secretion, thereby maintaining mineral homeostasis.

Adverse reactions to Hidroferol are generally related to alterations in calcium balance and individual sensitivity.

Common

• Mild hypercalcemia (elevated blood calcium levels)
• Nausea or gastrointestinal discomfort
• Constipation or abdominal cramps
• Headache
• Fatigue or generalized weakness

Serious

• Severe hypercalcemia leading to cardiac arrhythmias
• Nephrolithiasis (kidney stone formation)
• Acute pancreatitis associated with high calcium
• Hypersensitivity reactions such as rash, pruritus, or anaphylaxis
• Persistent elevation of serum calcium requiring medical intervention

Before initiating Hidroferol, certain health considerations should be evaluated to minimize risk.

• Assess baseline serum calcium, phosphate, and renal function.
• Use with caution in patients with a history of hypercalcemia or hyperparathyroidism.
• Monitor closely in individuals with chronic kidney disease or impaired renal clearance.
• Pregnancy and lactation status should be confirmed; discuss potential risks with a healthcare professional.
• Concomitant use of high-dose calcium or vitamin D supplements may increase the risk of hypercalcemia.
• Regular laboratory monitoring is recommended during long‑term therapy.

Hidroferol may interact with other medications that influence calcium metabolism or vitamin D pathways.

Avoid

• Thiazide diuretics, which can reduce calcium excretion and exacerbate hypercalcemia.
• High‑dose calcium supplements taken without medical supervision.
• Vitamin A excess, which may increase the risk of hypercalcemia when combined with calcifediol.

Use with caution

• Bisphosphonates, as concurrent therapy may affect bone turnover markers.
• Glucocorticoids, which can alter vitamin D metabolism and require dose adjustments.
• Anticonvulsants (e.g., phenytoin, phenobarbital) that increase vitamin D catabolism.
• Loop diuretics, which may affect calcium balance and require monitoring.